Haemonetics Corporation (HAE)
NYSE: HAE · Real-Time Price · USD
55.71
+0.38 (0.70%)
May 5, 2026, 10:45 AM EDT - Market open
Haemonetics Revenue
Haemonetics had revenue of $338.97M in the quarter ending December 27, 2025, a decrease of -2.75%. This brings the company's revenue in the last twelve months to $1.32B, down -4.02% year-over-year. In the fiscal year ending March 29, 2025, Haemonetics had annual revenue of $1.36B with 3.95% growth.
Revenue (ttm)
$1.32B
Revenue Growth
-4.02%
P/S Ratio
1.96
Revenue / Employee
$436,082
Employees
3,023
Market Cap
2.59B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 29, 2025 | 1.36B | 51.76M | 3.95% |
| Mar 30, 2024 | 1.31B | 140.40M | 12.01% |
| Apr 1, 2023 | 1.17B | 175.46M | 17.67% |
| Apr 2, 2022 | 993.20M | 122.73M | 14.10% |
| Apr 3, 2021 | 870.46M | -118.02M | -11.94% |
| Mar 28, 2020 | 988.48M | 20.90M | 2.16% |
| Mar 30, 2019 | 967.58M | 63.66M | 7.04% |
| Mar 31, 2018 | 903.92M | 17.81M | 2.01% |
| Apr 1, 2017 | 886.12M | -22.72M | -2.50% |
| Apr 2, 2016 | 908.83M | -1.54M | -0.17% |
| Mar 28, 2015 | 910.37M | -28.14M | -3.00% |
| Mar 29, 2014 | 938.51M | 46.52M | 5.22% |
| Mar 30, 2013 | 891.99M | 164.15M | 22.55% |
| Mar 31, 2012 | 727.84M | 51.15M | 7.56% |
| Apr 2, 2011 | 676.69M | 31.26M | 4.84% |
| Apr 3, 2010 | 645.43M | 47.55M | 7.95% |
| Mar 28, 2009 | 597.88M | 81.44M | 15.77% |
| Mar 29, 2008 | 516.44M | 66.83M | 14.86% |
| Mar 31, 2007 | 449.61M | 29.87M | 7.12% |
| Apr 2, 2006 | 419.73M | 36.14M | 9.42% |
| Apr 2, 2005 | 383.60M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AdaptHealth | 3.24B |
| Integer Holdings | 1.86B |
| LivaNova | 1.39B |
| Inspire Medical Systems | 915.25M |
| Neogen | 870.56M |
| iRhythm Holdings | 787.85M |
| NovoCure | 674.41M |
| TransMedics Group | 605.49M |
HAE News
- 11 days ago - New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures - PRNewsWire
- 4 weeks ago - Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2026 Results: May 7, 2026 - PRNewsWire
- 5 weeks ago - Haemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP® XL Venous Vascular Closure System - PRNewsWire
- 2 months ago - Haemonetics Transcript: 47th Annual Raymond James Institutional Investor Conference - Transcripts
- 2 months ago - Haemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS Technology - PRNewsWire
- 2 months ago - Haemonetics to Present at Raymond James 47th Annual Institutional Investors Conference - PRNewsWire
- 3 months ago - These Analysts Revise Their Forecasts On Haemonetics After Q3 Earnings - Benzinga
- 3 months ago - Haemonetics Earnings Call Transcript: Q3 2026 - Transcripts